NBIX Key Statistics, Chart & Performance
The current stock price of NBIX is 140.6 USD. In the past month the price decreased by -7.48%. In the past year, price increased by 1.81%.
NBIX Latest News, Press Relases and Analysis
NBIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 1800
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What does NBIX do?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the current price of NBIX stock?
The current stock price of NBIX is 140.6 USD. The price decreased by -0.87% in the last trading session.
Does NBIX stock pay dividends?
NBIX does not pay a dividend.
What is the ChartMill rating of NEUROCRINE BIOSCIENCES INC stock?
NBIX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the number of employees for NEUROCRINE BIOSCIENCES INC?
NEUROCRINE BIOSCIENCES INC (NBIX) currently has 1800 employees.
What is NEUROCRINE BIOSCIENCES INC worth?
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 14.02B USD. This makes NBIX a Large Cap stock.
Who owns NEUROCRINE BIOSCIENCES INC?
You can find the ownership structure of NEUROCRINE BIOSCIENCES INC (NBIX) on the Ownership tab.
NBIX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX turns out to be only a medium performer in the overall market: it outperformed 52.91% of all stocks.
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues.
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 4.18. The EPS increased by 12.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.95% | ||
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| Debt/Equity | 0 |
NBIX Forecast & Estimates
35 analysts have analysed NBIX and the average price target is 181.85 USD. This implies a price increase of 29.33% is expected in the next year compared to the current price of 140.6.
For the next year, analysts expect an EPS growth of 55.94% and a revenue growth 21.48% for NBIX